Analyst Price Targets — EHAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 1:12 am | — | UBS | $13.80 | $13.60 | TheFly | Enhabit downgraded to Neutral from Buy at UBS |
| February 23, 2026 6:26 pm | — | Jefferies | $13.80 | $13.60 | TheFly | Enhabit downgraded to Hold from Buy at Jefferies |
| February 23, 2026 3:25 pm | — | Leerink Partners | $13.80 | $13.60 | TheFly | Enhabit price target raised to $13.80 from $9.50 at Leerink |
| February 23, 2026 3:22 pm | — | Truist Financial | $13.80 | $13.60 | TheFly | Enhabit price target raised to $13.80 from $10.50 at Truist |
| January 22, 2026 11:47 am | Michael Wiederhorn | Oppenheimer | $14.00 | $10.74 | TheFly | Enhabit upgraded to Outperform from Perform at Oppenheimer |
| January 8, 2026 8:03 am | — | Wolfe Research | $12.00 | $9.51 | StreetInsider | UBS Upgrades Enhabit Home Health & Hospice (EHAB) to Buy |
| January 7, 2026 12:05 pm | — | Truist Financial | $10.50 | $9.44 | TheFly | Enhabit initiated with a Hold at Truist |
| December 16, 2025 1:39 pm | — | Jefferies | $12.00 | $9.73 | TheFly | Enhabit price target raised to $12 from $11 at Jefferies |
| December 9, 2024 9:41 am | Brian Tanquilut | Jefferies | $9.50 | $7.73 | StreetInsider | Jefferies Upgrades Enhabit Home Health & Hospice (EHAB) to Buy |
| May 14, 2024 6:14 am | Whit Mayo | Leerink Partners | $8.50 | $8.64 | TheFly | Enhabit upgraded to Market Perform from Underperform at Leerink |
Latest News for EHAB
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Enhabit, Inc. (NYSE: EHAB) to Kinderhook Industries, LLC. Under the terms of the proposed transaction, shareholders of Enhabit will receive $13.80 per share in cash. KSF is seeking to determine whether this…
DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB) (“Enhabit” or the “Company”), a leading home health and hospice care provider, today announced that it will hold the special meeting of stockholders (the “Special Meeting”) on May 12, 2026, at 8 a.m. CDT, to vote on the previously announced agreement and plan of merger (the “Merger Agreement”). Pursuant to the Merger Agreement, Anchor Merger Sub, Inc., a Delaware…
JPMorgan Chase and Co. lowered its holdings in shares of Enhabit, Inc. (NYSE: EHAB) by 48.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 291,823 shares of the company's stock after selling 271,731 shares during the period. JPMorgan
Selectis Health (OTCMKTS:GBCS - Get Free Report) and Enhabit (NYSE: EHAB - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations. Analyst Recommendations This is a breakdown of current
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EHAB.
U.S. House Trading
No House trades found for EHAB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.